ArticleScientific reports2025
AI-driven drug discovery using a context-aware hybrid model to optimize drug-target interactions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Constrained Disorder Principle: A Paradigm Shift for Accurate Interactome Mapping and Information Analysis in Complex Biological Systems.Bioengineering (Basel, Switzerland) · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Drug discovery is a challenging and resource-intensive process characterized by high costs, prolonged development timelines, and regulatory hurdles in the pharmaceutical sector. AI-driven recommendation systems have emerged as an effective approach to enhance candidate selection and optimize drug-target interactions. Typical drug discovery methods are expensive, time-consuming, and frequently have a high failure rate. The inability to quickly identify suitable drug candidates is a significant challenge due to the lack of effective predictive models. To address these issues, the Context-Aware Hybrid Ant Colony Optimized Logistic Forest (CA-HACO-LF) model is proposed. This model combines ant colony optimization for feature selection with logistic forest classification, improving drug-target interaction prediction. By incorporating context-aware learning, the model enhances adaptability and accuracy in drug discovery applications. The research utilized a Kaggle dataset containing over 11,000 drug details. During pre-processing, techniques such as text normalization (lowercasing, punctuation removal, and elimination of numbers and spaces) were applied. Stop word removal and tokenization ensured meaningful feature extraction, while lemmatization refined the word representations to enhance model performance. Feature extraction was further improved using N-grams and Cosine Similarity to assess the semantic proximity of drug descriptions, aiding the model in identifying relevant drug-target interactions and evaluating textual relevance in context. In the classification phase, the CA-HACO-LF model integrates a customized Ant Colony Optimization-based Random Forest (RF) with Logistic Regression (LR) to enhance predictive accuracy in identifying drug-target interactions, leveraging the extracted features and cosine similarity for better performance. The implementation is performed using Python for feature extraction, similarity measurement, and classification. The proposed CA-HACO-LF model outperforms existing methods, demonstrating superior performance across various metrics, including accuracy (0.986%), precision, recall, F1 Score, RMSE, AUC-ROC, MSE, MAE, F2 Score, and Cohen's Kappa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.